Cost of Revenue Comparison: Merck & Co., Inc. vs Xenon Pharmaceuticals Inc.

Merck vs Xenon: A Decade of Cost Evolution

__timestampMerck & Co., Inc.Xenon Pharmaceuticals Inc.
Wednesday, January 1, 2014167680000005903000
Thursday, January 1, 2015149340000002762000
Friday, January 1, 2016138910000001114000
Sunday, January 1, 20171277500000025573000
Monday, January 1, 2018135090000006000000
Tuesday, January 1, 20191411200000038845000
Wednesday, January 1, 20201361800000050523000
Friday, January 1, 20211362600000075463000
Saturday, January 1, 202217411000000105767000
Sunday, January 1, 202316126000000167512000
Loading chart...

Infusing magic into the data realm

Cost of Revenue: A Tale of Two Companies

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. Merck & Co., Inc., a titan in the field, has consistently maintained a high cost of revenue, averaging around $14.7 billion annually from 2014 to 2023. In contrast, Xenon Pharmaceuticals Inc., a smaller player, has seen its cost of revenue grow significantly, from a modest $5.9 million in 2014 to $167.5 million in 2023, marking a staggering increase of over 2700%.

A Decade of Change

While Merck's cost of revenue fluctuated slightly, peaking at $17.4 billion in 2022, Xenon's growth trajectory highlights its expanding operations and market presence. This comparison underscores the diverse strategies and scales of operation within the pharmaceutical sector. As Xenon continues to grow, it will be interesting to see how its cost structure evolves in the coming years.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025